BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-491@pharmaconomics
DTSTAMP:20260707T022024Z
DTSTART;VALUE=DATE:20260406
DTEND;VALUE=DATE:20260407
SUMMARY:PRAX Phase 2 — elsunersen
DESCRIPTION:Phase 2 trial results for elsunersen in SCN2A development and epileptic encephalopathy are due Apr 6\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000066/prax-20260622.htm\n\nTrack it: https://www.pharmaconomics.com/e/491
URL:https://www.pharmaconomics.com/e/491
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PRAX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR